Samantha K Holden1, Taylor Finseth2, Stefan H Sillau1, Brian D Berman1,3. 1. Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO USA. 2. Department of Neurology, Aurora St. Luke's Medical Center, Milwaukee, WI. 3. Neurology Section, Denver VA Medical Center, Denver, CO USA.
Abstract
BACKGROUND: The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established. OBJECTIVE: Determine progression rates of MDS-UPDRS scores in de novo PD. METHODS: 362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included. Longitudinal progression of MDS-UPDRS total and subscale scores were modeled using mixed model regression. RESULTS: MDS-UPDRS scores increased in a linear fashion over five years in de novo PD. MDS-UPDRS total score increased an estimated 4.0 points/year, Part I 0.25 points/year, Part II 1.0 points/year, and Part III 2.4 points/year. CONCLUSIONS: The expected average progression of MDS-UPDRS scores in de novo PD from this study can assist in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.
BACKGROUND: The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established. OBJECTIVE: Determine progression rates of MDS-UPDRS scores in de novo PD. METHODS: 362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included. Longitudinal progression of MDS-UPDRS total and subscale scores were modeled using mixed model regression. RESULTS: MDS-UPDRS scores increased in a linear fashion over five years in de novo PD. MDS-UPDRS total score increased an estimated 4.0 points/year, Part I 0.25 points/year, Part II 1.0 points/year, and Part III 2.4 points/year. CONCLUSIONS: The expected average progression of MDS-UPDRS scores in de novo PD from this study can assist in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Adrienne Henderson-Smith; Kathleen M Fisch; Jianping Hua; Ganqiang Liu; Eugenia Ricciardelli; Kristen Jepsen; Mathew Huentelman; Gabriel Stalberg; Steven D Edland; Clemens R Scherzer; Travis Dunckley; Paula Desplats Journal: Epigenetics Date: 2019-03-14 Impact factor: 4.528
Authors: Kevin B Wilkins; Matthew N Petrucci; Yasmine Kehnemouyi; Anca Velisar; Katie Han; Gerrit Orthlieb; Megan H Trager; Johanna J O'Day; Sudeep Aditham; Helen Bronte-Stewart Journal: J Parkinsons Dis Date: 2022 Impact factor: 5.520
Authors: Rong Ye; Joseph J Locascio; Anna E Goodheart; Moqing Quan; Baorong Zhang; Stephen N Gomperts Journal: Parkinsonism Relat Disord Date: 2021-02-17 Impact factor: 4.891